Kornimate/medical-research-clean huggingface dataset:
sonoguided-microwave uterine myoma

Conditions: Obstetric/Gynecology

Summary: this study mainly evaluates the resolution of uterine fibroids by microwave ablation. the medical equipment used is ke hui. "the ampening ablation system is a percutaneous surgery. during laparoscopic surgery, it is directly ablated and soft, including problems that cannot be solved by partial or complete tissue ablation. "hydrogen is used. if the expected range of ablation can be found, there is no need to wait for 3 to 6 months for ablation slowly like haifu surgery. a fast, small, high-quality treatment that provides reference for medical treatment and helps doctors choose the most suitable treatment.

a collection of 20 women suffering from uterine fibroids were treated with microwave fibroids ablation for symptoms of uterine fibroids, and they could be discharged the next day or two days after surgery. schedule return visits and routine blood tests according to clinical needs, and follow up with ultrasound and questionnaires during routine return visits (1, 3, and 6 months) after surgery. in the third month after surgery, there will be another imaging report. magnetic resonance imaging and blood tests are used to compare the changes of patients' fibroids, their physiological recovery status, and the degree of improvement in their quality of life.

Eligibility criteria:
inclusion criteria: 1. women who have reached the age of 20 and have not yet menopause. 2. myoma size≧4cm. 3. patients with submucosal fmyoma or intramural myoma of the uterus. exclusion criteria: 1. patients with subserosal myoma. 2. pregnant, breastfeeding or have menopause. 3. pelvic infections, vaginitis, cervicitis or endometritis and have not been cured. 4. malignant diseases of the cervix and uterus. 5. abnormal reports of clinical significance in pap smear or thin-layer cell test. 6. abnormal blood coagulation function or liver and kidney function, with bleeding tendency. 7. there is no safe puncture treatment route. 8. those who have installed intrauterine contraceptive device or pacemaker. 9. those who cannot perform vaginal ultrasound, such as those who have no sexual experience and do not accept hymen repair.

Keywords: microwave uterine myoma
prevention of severe acute graft-versus-host disease in pediatric patients using a dagoat model

Conditions: Transplant-Related Disorder

Summary: to evaluate the efficacy and safety of ruxolitinib for prophylactic therapy of child patients who are predicted to have a high risk for developing severe acute graftversus-host disease (agvhd) by the dynamic agvhd onset anticipation tianjin (dagoat) model.

this study aims to prospectively evaluate the use of the dagoat model in real-world clinical settings at the institute of hematology, chinese academy of medical sciences (ihcams).

Eligibility criteria:
inclusion criteria: 1. patients must be ≤ 16 years of age; 2. patients receiving human leukocyte antigen mismatched and non-cord blood allogeneic hematopoietic stem cell transplantation; 3. patients who can take oral medication; 4. patients or their guardians have to sign an informed consent form before the start of the research procedure. exclusion criteria: 1. tandem transplantation or multiple transplantations; 2. patients who are allergic to or cannot tolerate ruxolitinib; 3. mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements; 4. patients who are pregnant or cannot take appropriate contraceptive measures during treatment; 5. patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.
motexafin gadolinium plus radiation therapy to the brain in treating patients with newly diagnosed glioblastoma multiforme

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: radiation therapy uses high-energy x-rays to damage tumor cells. drugs such as motexafin gadolinium may make tumor cells more sensitive to radiation therapy. purpose: phase ii trial to study the effectiveness of motexafin gadolinium plus radiation therapy to the brain in treating patients who have newly diagnosed glioblastoma multiforme.

objectives: i. assess the safety of motexafin gadolinium and cranial irradiation, in terms of dose-limiting toxicity and clinically significant adverse events, in patients with newly diagnosed glioblastoma multiforme. ii. evaluate the pharmacokinetics of this regimen in these patients. iii. determine the survival of patients treated with this regimen. iv. assess the activities of daily living and neurological status of patients treated with this regimen. outline: this is a multicenter study. patients receive motexafin gadolinium iv over 30 minutes on days 1-5 of weeks 1 and 2, and on days 1, 3, and 5 of weeks 3-6. patients undergo cranial irradiation on days 1-5 of weeks 1-6. treatment continues in the absence of disease progression or unacceptable toxicity. patients undergo a neurological examination and an activities of daily living questionnaire at baseline, week 10, and during follow-up visits. patients are followed at weeks 10 and 16 and then every 2 months thereafter. projected accrual: a total of 20 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically confirmed glioblastoma multiforme (gbm) grade iv astrocytoma located supratentorially at least 2 weeks and no more than 4 weeks since prior surgery for gbm no recurrent disease patient characteristics: age: 18 and over performance status: karnofsky 70-100% life expectancy: not specified hematopoietic: absolute neutrophil count at least 1,500/mm3 platelet count at least 50,000/mm3 hepatic: bilirubin no greater than 3.0 mg/dl ast and alt no greater than 2 times upper limit of normal (uln) alkaline phosphatase no greater than 2 times uln renal: creatinine no greater than 2.0 mg/dl other: hiv negative no history of porphyria no glucose-6-phosphate dehydrogenase deficiency no other malignancy within the past 5 years except carcinoma in situ of the cervix or nonmelanoma skin cancer not pregnant or nursing negative pregnancy test fertile patients must use effective contraception prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior antineoplastic agent for gbm no concurrent chemotherapy during and for 2 weeks after study no other concurrent antineoplastic investigational agent endocrine therapy: prior and concurrent corticosteroids allowed radiotherapy: no prior radiotherapy to the brain surgery: see disease characteristics other: concurrent anticonvulsants allowed other concurrent cancer therapy allowed if medically necessary

Keywords: adult glioblastoma adult giant cell glioblastoma adult gliosarcoma
causes of appetite loss in patients with chronic obstructive pulmonary disease (copd)

Conditions: COPD

Summary: the project looks at causes of appetite loss in patients with copd. it is know that active systemic inflammation can lead to appetite loss and copd is classified as a disease lead by inflammation. but it has never been investigated if the patient with copd has other causes of appetite loss such as physical, psychological or social barriers for not reaching a sufficient dietary intake. the study uses a homemade questionnaire, the cat-scale and the cnaq-score to evaluate the extent of appetite loss and certain demographic characteristics of the participants. there will be made correlation analysis for cnaq-score and continuous variables and there will be tested for significant differences between the group who scores as low appetite and the group that scores with a normal appetite via cnaq. the second part of the study invites patients to participate in a semi-structured interview, that focuses on the patient's experience with appetite loss, meals and food. the interviews will be transcribed and analysed.


Eligibility criteria:
inclusion criteria: * copd diagnosis exclusion criteria: * none
pioglitazone on cardiac function and large arteries (piccola study)

Conditions: Diabetes

Summary: this study aims to use a novel, sensitive, non-invasive scanning technique to investigate the effects of insulin-sensitizing agent pioglitazone, on heart and artery function.

the prevalence of diabetes mellitus and impaired glucose tolerance are nearing epidemic proportions in developed societies. for example in the usa \>16 million individuals have diabetes and this number is predicted to double over the next two decades. diabetes is a major risk factor for death and disability, primarily from cardiovascular disease (cvd). the mechanisms of how diabetes increases the risk of developing cvd are not fully understood. it is evident from previous studies that diabetes has an adverse effect on both artery and heart function. what is emerging from recent studies is that it is likely that these proven dysfunctions in the arteries and heart interact to increase the risk of cvd. insulin-sensitizing agents, such as pioglitazone, may have a beneficial effect on heart and artery function. this study aims to further our understanding of the effect of these agents on heart and artery using a novel, sensitive, non-invasive scanning technique to investigate the effects of this group of drugs on heart and artery function. this is a prospective double-blind randomised crossover study comparing the insulin-sensitizing drug, pioglitazone with a placebo in 24 volunteers. following a \>1 week run-in period subjects will be randomised double-blind to 1 of 2 treatment sequences. subjects will either receive the active drug (pioglitazone 45mg/day) for a 12 week period, followed by a 2 week washout and then the placebo drug for 12 weeks or they will receive the placebo drug for 12 weeks, followed by the 2 week washout and 12 weeks of the active drug (pioglitazone 45mg/day). this design was chosen to test the null hypothesis that the active drug will have no effect on diastolic heart function. the use of a placebo is essential to ensure that any benefits found can be attributed to the active drug. the design also allows us to minimise the number of subjects needed and is the gold standard approach to avoid observer bias.

Eligibility criteria:
inclusion criteria: * male or female of any age with type 2 diabetes exclusion criteria: * subjects will be excluded if they have any of the following: * known coronary heart disease, * patients receiving insulin, * uncontrolled hypertension (i.e. \>160mmhg systolic or \>95mmhg diastolic), * systolic dysfunction (ejection fraction \<50%), * heart valve disease, * proliferative or pre-proliferative retinopathy, * severe hepatic or renal impairment. * possible pregnancy * malignancy

Keywords: diabetes tissue doppler imaging wave intensity analysis.
study in children who have switched to isosource junior mix formula

Conditions: Cerebral Palsy

Summary: a retrospective study in children who have switched to isosource junior mix formula (ricimix study) will review paediatric children \> 12 months of age who require isosource junior mix as an enteral tube feeding formula and have consumed the formula for at least 1 month. the purpose of this study is to understand if there has been an improvement in outcomes/ experiences * the current usage of isjmix formula in children who require blended diets * improved feeding intolerances * improved patient outcomes/ experiences

retrospective data will be collected using questionnaire by the dietitians at the nutrition and dietetic department. all completed questionnaires will be sent back to nestle health science/ cro company. the primary objectives: the following measures will be collected retrospectively after 1 month use of isjmix * feeding tolerance \[no change, tolerance improved, tolerance worsened\]: gastric residuals, gagging/retching, vomiting, abdominal distention/ gas, stool consistency issues (too hard, too loose) * volume of formula consumed in a day the secondary objective is to collect restropective data on: * any improved patient outcomes noted * calculate the potential cost savings made when using isjmix to help manage the feeding intolerances * calculate the potential costs benefit of using isjmix over other standard formulas

Eligibility criteria:
inclusion criteria: * all children who are using isosource junior mix as tube feed formula exclusion criteria: * all children who did not switch to isosource junior mix feed formula
adductor canal block and ipack block vs. isolated adductor canal block for post-operative analgesia following hto/dfo/tto

Conditions: Analgesia

Summary: a randomized, single-blind, single-center study measuring the effects of adductor canal block combined with ipack infiltration compared to adductor canal block alone on post-operative pain and opioid consumption in patients undergoing high tibial osteotomy (hto)/distal femoral osteotomy (dfo)/tibial tubercle osteotomy (tto).


Eligibility criteria:
inclusion criteria: * patients between 18 and 75 years of age * patients undergoing hto/dfo/tto. * american society of anesthesiologists (asa) i or ii exclusion criteria: * patients younger than 18 and older than 75. * patients with multi-ligament injury * patients undergoing concomitant cartilage procedure or aclr. * patients with a history of chronic pain that have used opioids for pain management for 3 months or longer. * patients who are allergic to oxycodone; * patients with diagnosed or self-reported cognitive dysfunction; * patients with a history of neurologic disorder that can interfere with pain sensation; * patients with a history of drug or recorded alcohol abuse; * patients who are unable to understand or follow instructions; * patients with severe liver disease, renal insufficiency, congestive heart failure, and/or significant heart disease; * patients with an allergy or contraindication to any of the medications used in the study, or patients with a contraindication to any study procedures; * patients with a bmi over 45; * any patient that the investigators feel cannot comply with all study related procedures; * any pregnant patient; assessed via urine pregnancy test in the preoperative area as part of standard preoperative surgical protocol;
covid-19 fourth dose study in australia

Conditions: COVID-19

Summary: this clinical trial will be a blinded, randomised study to determine the safety, reactogenicity, and immunogenicity of a second booster dose of sars-cov-2 vaccines in adults enrolled over two consecutive stages. stage 1 will commence at the time of study approval and transition to stage 2 once bivalent vaccines are approved and available in australia.

participants will be adults aged 18 years or older who have been previously primed with two doses of either pfizer-biontech (bnt162b2, or comirnaty®) or astrazeneca (chadox1-s, or vaxzevria®) and boosted at least 3 months earlier with pfizer biontech vaccine (30µg). there will be no upper age limit. participants will be recruited from the murdoch children's research institute, the royal children's hospital (rch), the peter doherty research institute, and, if necessary, the greater melbourne area. ideally, 100 participants will be recruited per group unless bivalent omicron-specific vaccines are introduced before this target is reached for monovalent ancestral vaccines. there will be 800 participants in total. procedures will be implemented to ensure participants of all ages (aged 18 and above) are included and that there is an even age distribution in each group (\<50 and ≥50 years).

Eligibility criteria:
inclusion criteria: 1. have completed a primary schedule of two doses of pfizer-biontech or astrazeneca vaccines and received a booster of pfizer-biontech vaccine (30µg) at least 3 months earlier. 2. no confirmed sars-cov-2 infection on pcr or rat within the last 3 months. 3. willing and able to give written informed consent. 4. aged 18 years or above. 5. willing to complete the follow-up requirements of the study. exclusion criteria: 1. currently receiving immunosuppressive medication or anti-cancer chemotherapy. 2. known hiv infection. 3. congenital immune deficiency syndrome. 4. received immunoglobulin or other blood products in the three months prior to potential study booster vaccination. 5. study staff and their relatives. 6. have a history of a severe allergic reaction to any covid-19 vaccines or have a medical exemption to receiving further covid-19 vaccines. 7. cannot read or understand english.

Keywords: booster dose moderna and pfizer mrna vaccine monovalent, bivalent
topical antibiotics in chronic rhinosinusitis

Conditions: Chronic Rhinosinusitis (Diagnosis)

Summary: researchers are trying to find out if patients develop antibiotic resistant organisms after the use of topical antibiotics in the treatment of chronic rhinosinusitis.

there is a certain group of patients that has chronic rhinosinusitis that has continued even with treatment including saline and steroid nasal irrigations as well as oral steroids and antibiotics and surgery. in these patients, the use of topical antibiotic nasal rinses may be of benefit to their disease. the use of topical antibiotic nasal rinses is commonly used as standard of care already throughout the country for refractory chronic rhinosinusitis including here at the mayo clinic. our pharmacy has compounded this medication for this specific purpose. as such, this study is not aimed at a 'novel medication', but rather to investigate the efficacy of a medication already in common use but without great evidence. the investigators are doing this research study to find out if patients develop antibiotic resistant organisms after the use of topical antibiotics in the treatment of chronic rhinosinusitis. in addition, this study will look at the effects of topical antibiotics on patient symptoms as measured by a patient survey called the sino-nasal outcomes test (snot-22) and in-office an exam of the inside of their nose, including with a scope (a camera on the end of a long tube).

Eligibility criteria:
inclusion criteria: * male or female, between 18-80 years old, diagnosed with chronic rhinosinusitis who have undergone previous functional endoscopic sinus surgery including at minimum maxillary antrostomy and anterior ethmoidectomy * active mucopurulence on endoscopic examination with corresponding culture demonstrating pathogenic bacterial growth * completion of written informed consent * no prior enrollment into this study * refractory to maximal medical therapy exclusion criteria: * patient has not had prior endoscopic sinus surgery consisting of at minimum maxillary antrostomy and anterior ethmoidectomy * patient is currently being treated with oral antibiotics * patient has been treated with oral or topical antibiotics within the past 14 days * participation in an investigational drug study simultaneously with participation in this study * concurrent use of oral steroids * allergy to tobramycin, mupirocin, gentamicin and levofloxacin * known to currently be pregnant
the effect of allopurinol on insulin resistance and blood pressure

Conditions: Metabolic Syndrome

Summary: studies in animals have found that allopurinol can markedly improve fructose induced metabolic syndrome. in this study we test the hypothesis that allopurinol may lower bp, reduce triglycerides, and improve metabolic parameters in subjects placed on a high fructose diet.

60 male subjects, age 40 to 65 years of age, will be placed on a 3500kcal (55% carbohydrates containing 200 g fructose) for 2 weeks. half will receive allopurinol mg/day (randomized). at the end of 2 weeks we measure a variety of parameters including fasting glucose and insulin levels (with calculation of homa index), serum lipids (including triglycerides and ldl/hdl cholesterol), sitting blood pressure, serum uric acid, weight, and various other measurements (c reactive protein, adiponectin and leptin levels, and urate redox products). primary endpoint is insulin resistance. secondary endpoints are blood pressure, lipids, uric acid, weight.

Eligibility criteria:
inclusion criteria: * males, age 40 -65 yrs exclusion criteria: * none

Keywords: uric acid fructose hypertension insulin glucose homa
walk study: women's active living for koreans study

Conditions: Physical Activity; Metabolic Syndrome; Lifestyle, Sedentary

Summary: the prevalence of metabolic syndrome (mets) is a health concern among asians. growing evidence indicates that korean americans had higher mets prevalence compared to non-hispanic whites, but a culturally and linguistically appropriate lifestyle intervention has not been developed for korean american middle-aged and older women. thus, the investigators propose to develop a 4-week lifestyle intervention (women's active living for koreans (walk) study) to increase physical activity (pa) and reduce sedentary behavior for korean american women.

the purpose of this pilot study is to develop a 4-week lifestyle intervention (women's active living for koreans (walk) study) to increase physical activity (pa) and reduce sedentary behavior for korean american women. the investigators will assess feasibility and acceptability of the walk study and potential efficacy of the walk study on outcomes including sedentary behavior and pa.

Eligibility criteria:
inclusion criteria: * self-identified korean-speaking korean american women * sedentary lifestyle at work and/or during leisure time * aged between 40 and 69; 4) intention to be physically active * kakaotalk user exclusion criteria * medical conditions or physical problems requiring a special care exercise program * known bone or join problems that impair the ability to do moderate physical activity * participating in a lifestyle modification program or research study * planning a trip out of the u.s. during the next 2 months * pregnancy.
accuracy of endomyometrial biopsy in diagnosis of adenomyosis

Conditions: Adenomyosis

Summary: this study will compare the accuracy of diagnosing adenomyosis by obtaining hysteroscopic guided endomyometrial biopsy and comparing it to accuracy of diagnosis by transvaginal ultrasound and magnetic resonance imaging.

preoperative diagnosis of adenomyosis is usually difficult. the use of ultrasound and mri for preoperative diagnosis is still of low positive predictive values. the majority of cases of adenomyosis are diagnosed postoperatively after justo pathological examination of the hysterectomy specimens. the introduction of the concept of preoperative diagnosis of adenomyosis through a hysteroscopic endomyometrial biopsies may be a very good method for preoperative diagnosis of this condition. participants patients who are diagnosed as adenomyosis by ultrasound and mri and scheduled for hysterectomy will undergo an endomyometrial biopsy. the accuracy of this method, its sensitivity, specificity, positive and negative predictive values of this method will be compared with the conventional methods for preoperative diagnosis of adenomyosis after final diagnosis by final gusto pathological diagnosis of hysterectomy specimens.

Eligibility criteria:
inclusion criteria: * patients diagnosed with abnormal uterine bleeding due to adenomyosis diagnosed by transvaginal ultrasound and mri and scheduled for hysterectomy exclusion criteria: * hysterectomy not performed * incomplete ultrasound and mri information